Nourish, a startup that develops nutritional programmes designed to amplify the effects of GLP-1 weight-loss medications, has raised $100 million from Menlo Ventures, Thrive Capital, Index Ventures, and JPMorgan — a haul that signals how deeply the pharmaceutical reshaping of the body has penetrated the worlds of beauty, wellness, and fashion.
The premise is deceptively simple: GLP-1 drugs like semaglutide suppress appetite and alter metabolism, but they do not teach the body how to nourish itself. Nourish’s protocols — a combination of meal plans, micronutrient tracking, and behavioural coaching — aim to preserve muscle mass and bone density during rapid weight loss, addressing the aesthetic anxieties that the drugs themselves have created.
The implications for the fashion industry are tectonic. As GLP-1 usage proliferates — estimates suggest tens of millions of users globally by 2027 — the silhouette that designers design for is shifting. Sample sizes that once accommodated a range of bodies now confront a narrower, drug-altered reality. The conversation about inclusivity, already fraught, acquires a new dimension when the body itself becomes a site of pharmacological intervention.
Fashion has always metabolised cultural change through fabric and form. The corset, the bustle, the power shoulder — each was a response to a shift in how the body was perceived. GLP-1s represent a shift not in perception but in physiology, and the industry is only beginning to reckon with what that means for grading, fit, and the very idea of a standard size.
Nourish’s investors are betting that managing the side effects and long-term outcomes of these drugs will become as lucrative as the drugs themselves. Whether that bet pays off, the deeper question lingers: in an industry built on the manipulation of silhouette, what happens when the silhouette starts changing faster than the seams can follow?
